

Press release

Zug, 17 December 2009

HBM BioVentures portfolio company: Financing round for Ophthotech

Ophthotech, the seventh-largest private investment holding in the HBM BioVentures portfolio, has completed a USD 30 million financing round. It was led with USD 15 million by a new investor, Clarus Ventures, which is specialised in the healthcare sector. Ophthotech's valuation in this round of financing corresponds to the current valuation of the investment in HBM BioVentures' books.

HBM BioVentures has invested USD 14.4 million in Ophthotech since August 2007. The new financing round enables the company to conduct a Phase II study into its lead drug, E10030 for visual gain. The terms of this round of financing confirm the current valuation of HBM BioVentures' investment in Ophthotech. HBM BioVentures participated with USD 2.1 million in the financing, corresponding to half of its percentage holding in the company.

Ophthotech Corp., which has its head office in Princeton, New Jersey, USA, specialises in developing therapies to treat eye conditions. The company has particular specialist expertise in the field of macular degeneration. In its Phase I combination therapy trial, E10030, which targets PDGF, has demonstrated unprecedented visual gain in patients with wet AMD. This remarkable visual outcome was accompanied for the first time by robust neovascular regression, reflecting the disruption of underlying pathology. According to Ophthotech, E10030 has the potential of becoming a new standard for wet AMD treatment. For more information on Ophthotech, please consult www.opthotech.com.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

HBM BioVentures Ltd

As a venture capital company, HBM BioVentures is invested globally in some 35 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on emerging companies that are not yet listed, with two-thirds of assets invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN). Visit www.hbmbioventures.com.

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com